10-K: Palisade Bio Shifts Focus to Novel IBD Therapies Following Disappointing Trial Results

Palisade Bio pivots to pre-clinical development of PALI-2108 for inflammatory bowel disease after terminating its LB1148 program.

Summary

• Palisade Bio has refocused its business on developing novel therapies for autoimmune, inflammatory, and fibrotic diseases, particularly inflammatory bowel disease (IBD).
• The company's lead product candidate, PALI-2108, is a prodrug PDE4 inhibitor targeting ulcerative colitis (UC) and Crohn's disease (CD).
• This shift follows the termination of the LB1148 program after Phase 2 trial results did not meet the primary endpoint.
• Pre-clinical development of PALI-2108 is being jointly undertaken with Giiant Pharma, with Palisade assuming all costs after IND or CTA approval.
• The company plans to submit an IND/CTA in the third quarter of 2024 and initiate clinical trials in the fourth quarter of 2024.
• A Phase 1a SAD/MAD trial is expected to have topline data in the first half of 2025, followed by a Phase 1b/2 POC trial in the second half of 2025.
• PALI-1908, another oral PDE4 inhibitor prodrug, is in the research stage with pre-clinical development planned for the first half of 2025.
• The company is also developing a biomarker-based patient selection approach to improve clinical response rates.
• Palisade Bio has expressed substantial doubt about its ability to continue as a going concern and will require additional funding to support its operations.
• The company reported a net loss of $12.3 million for the year ended December 31, 2023.

Sentiment

Score: 4

Explanation: The document highlights a strategic shift and promising pre-clinical data, but is overshadowed by financial concerns and the termination of a key program. The overall sentiment is cautiously optimistic with significant risks.

Positives

• PALI-2108 has shown promising results in pre-clinical models, demonstrating dose-dependent efficacy and minimal systemic toxicity.
• The company is developing a biomarker-based patient selection approach, which could improve clinical response rates.
• The company has secured a worldwide license to all of Giiant Pharma's current and future products.
• The company has a clear timeline for the development of PALI-2108, with plans to submit an IND/CTA in the third quarter of 2024 and initiate clinical trials in the fourth quarter of 2024.

Negatives

• The company terminated the development of LB1148 after its Phase 2 PROFILE study failed to meet the primary endpoint.
• Palisade Bio has expressed substantial doubt about its ability to continue as a going concern.
• The company has a history of net losses and expects to continue to incur net losses.
• The company has received a delisting notification from the Nasdaq Stock Market based on its Bid Price being under $1.00 for thirty (30) consecutive trading days.
• The company has received a notification from the Nasdaq Stock Market that its audit committee does not have three (3) independent members as a result of recent director resignations.

Risks

• The company's business depends on the successful development and commercialization of PALI-2108, which is subject to substantial risks.
• The company depends on its license agreement with Giiant, and termination of this agreement could harm its business.
• The company will require substantially more capital than it currently has, and there is no guarantee that it will be able to secure additional funding.
• There is no assurance that the company's product candidates will obtain regulatory approval.
• The company may not be able to obtain, maintain, or enforce global patent rights or other intellectual property rights.
• The company's common stock price may be highly volatile.
• The company may be subject to product liability claims.
• The company may not be able to attract and retain senior management and scientists with relevant expertise.

Future Outlook

The company plans to submit an IND/CTA in the third quarter of 2024 and initiate clinical trials of PALI-2108 in the fourth quarter of 2024. Topline data from the Phase 1a SAD/MAD trial is expected late in the first half of 2025. Following the completion of the Phase 1a SAD/MAD trial, the company plans to initiate a Phase 1b/2 POC trial in UC patients in the second half of 2025.

Industry Context

The company is operating in a competitive landscape within the biopharmaceutical industry, focusing on PDE4 inhibitor prodrugs and precision medicine for IBD. The company faces competition from established pharmaceutical companies, emerging biotechnology companies, and generic manufacturers.

Comparison to Industry Standards

• The company's approach of using locally acting PDE4 inhibitors is a novel approach to IBD treatment, as systemically available PDE4 inhibitors have been limited by dose-limiting toxicity.
• The company's use of precision medicine for IBD is an unmet need in the industry, as precision medicine has been successfully applied in oncology but not yet widely adopted in IBD.
• The company's competitors include large pharmaceutical companies such as AbbVie, Johnson & Johnson, and Takeda, as well as emerging biotech companies and generic manufacturers.
• The company is not aware of other PDE4 inhibitors in development for ulcerative colitis (UC) or fibro stenotic Crohns disease.

Management Changes

Corporate Governance

Related Party Transactions

• The company has a consulting agreement with its former Chief Operating Officer.
• The company has a separation agreement with its former Chief Executive Officer.
• The company has a license agreement with the Regents of the University of California.

Stakeholder Impact

• Shareholders may experience dilution due to future equity offerings.
• Employees may be affected by potential future cost-reduction plans.
• Patients may benefit from the development of new therapies for IBD.
• Creditors may be at risk due to the company's going concern status.

Next Steps

• The company plans to submit an IND/CTA in the third quarter of 2024.
• The company plans to initiate clinical trials of PALI-2108 in the fourth quarter of 2024.
• The company plans to initiate pre-clinical development of PALI-1908 in the first half of 2025.

Key Dates

Keywords

PALI-2108, inflammatory bowel disease, IBD, ulcerative colitis, Crohn's disease, PDE4 inhibitor, biomarkers, clinical trials, Giiant Pharma, drug development